The following is a summary of “Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival,” published in ...

Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis, Johnson & Johnson’s Darzalex has been given the go-ahead for ...

Seymour said the Government had, in 2024, allocated Pharmac its largest-ever budget of $6.294 billion over four years, plus a ...

The patient may also experience an abnormally high or abnormally low blood pressure in nephrotic syndrome (DiSalvo et al., 2002; Khan & Falk, 2001). Amyloid protein can limit the ability of the ...

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months.

Paradox is focused on the development of treatment for immunoglobulin light chain amyloidosis (AL amyloidosis), a complication of multiple myeloma that can lead to heart, kidney and liver failure ...

The company also reported accelerated enrollment in the ongoing NEXICART-2 study, which is evaluating the safety and efficacy of NXC-201 in AL amyloidosis patients. NXC-201 is the only CAR-T ...

Lower skeletal muscle mass was associated with an increased risk for short- and long-term mortality in patients with cardiac amyloidosis (CA). This association was particularly strong with ...